Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13706075 | 0.84 | L3MBTL1 (0.36) | TDP1ALDH1A1HPGDMAPK1L3MBTL1 | |
| SCHEMBL4351667 | 0.84 | MEN1 (0.46) | TDP1ALDH1A1HPGDL3MBTL1MEN1 | |
| SCHEMBL4355833 | 0.83 | L3MBTL1 (0.36) | TDP1ALDH1A1HPGDMAPK1L3MBTL1 | |
| SCHEMBL18785900 | 0.83 | L3MBTL1 (0.36) | TDP1ALDH1A1HPGDMAPK1L3MBTL1 | |
| SCHEMBL4353897 | 0.81 | TDP1 (0.37) | TDP1ALDH1A1HPGDMAPK1L3MBTL1 | |
| SCHEMBL4360548 | 0.80 | ALDH1A1 (0.46) | TDP1ALDH1A1HPGDMAPK1L3MBTL1 | |
| SCHEMBL4355830 | 0.73 | ALDH1A1 (0.47) | ALDH1A1HPGDMAPK1NPC1RAB9A | |
| SCHEMBL4352150 | 0.73 | HPGD (0.39) | ALDH1A1HPGDMAPK1L3MBTL1NPC1 | |
| SCHEMBL12292324 | 0.69 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL12016489 | 0.68 | KMT2A (0.41) | TDP1ALDH1A1L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779183-B2 | Acid generating agent for chemically amplified resist compositions | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2014-07-15 | — | — | US | disclosed |
| US-20090234155-A1 | Acid generating agent for chemically amplified resist compositions | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234155-A1 | Acid generating agent for chemically amplified resist compositions | POLM, CBR1, PFAS | TDP1 3917/4885ALDH1A1 346/4885HPGD 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.